KRAS and pancreatic adenocarcinoma: [66–76] The only extracolonic GIT sites that showed marginally higher frequency of BRAF mutations are cholangiocarcinomas (1.3%), and KRAS wild-type pancreatic adenocarcinomas (0–3%).